V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20225073 | 20135017 | 1.6 | 85.2 | Palliative (P) | 2018-10-28 | 2018-10-29 | PHITT C SIOPEL-3HR | 02 | null | PHITT C SIOPEL-3HR | 100693247 |
| 20225534 | 20135018 | 1.55 | 53.4 | Palliative (P) | 2017-06-27 | 2018-12-01 | CISPLATIN + TEYSUNO | 02 | N | IRINOTECAN + RALTITREXED | 101407200 |
| 20001315 | 20135020 | 1.57 | 46.1 | null | 2018-06-02 | 2018-06-02 | Rituximab | 01 | N | ARISTOTLE TRIAL | 101739285 |
| 20012445 | 20135022 | 1.57 | 80.2 | Palliative (P) | 2020-07-19 | 2020-07-20 | NAB PACLITAXEL | 02 | N | COSMIC TRIAL | 100328123 |
| 20013659 | 20135023 | 1.8 | 62.8 | Palliative (P) | null | 2019-07-07 | Letrozole + Palbociclib | null | N | CARBOPLATIN + PEMETREXED | 100521861 |
| 20013726 | 20135024 | 1.71 | 61.45 | null | 2017-05-28 | 2017-06-16 | SCOPE 2 TRIAL | 01 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100700197 |
| 20015137 | 20135025 | 1.82 | 15 | Curative (C) | 2021-05-25 | 2021-06-18 | Hydroxycarbamide | 2 | N | HEPATOBLASTOMA HR CARBO/DOX | 100216967 |
| 20015188 | 20135026 | 1.71 | 63 | null | 2019-11-18 | 2019-11-20 | Letrozole + Palbociclib | 02 | null | BACILLUS CALMETTE-GUERIN | 101757171 |
| 20018993 | 20135029 | 1.65 | null | Neo-adjuvant (N) | 2018-11-19 | 2020-05-21 | Doxorubicin 75mg/m2 | 02 | N | DARATUMUMAB | 101406014 |
| 20021080 | 20135031 | 1.91 | 93 | null | 2018-09-01 | 2018-09-02 | STS Non-Rhabdo EpSSG 2005 Vcy | 02 | null | BORTEZOMIB + THALIDOMIDE | 100564750 |
| 20022615 | 20135032 | 1.81 | 65.2 | null | 2018-03-30 | 2018-08-25 | Doxorubicin + Olaratumab | 02 | N | FLUOROURACIL + RT | 101570575 |
| 20032659 | 20135036 | 1.75 | 44.7 | 03 | 2018-04-07 | 2018-04-14 | DA | 02 | N | CAP + RT | 101629700 |
| 20033541 | 20135038 | 1.58 | 76.8 | null | 2016-11-05 | 2017-03-23 | Cetuximab + Irinotecan (Cycle 1) | 02 | null | CEMIPLIMAB | 101695090 |
| 20034818 | 20135041 | null | null | null | 2018-08-01 | 2019-02-11 | Pemetrexed | 02 | N | ARISTOTLE TRIAL | 100774021 |
| 20035688 | 20135044 | null | null | null | 2018-11-24 | 2018-11-24 | CYCLOPHOSPHAMIDE + THALIDOMIDE | 02 | null | CISPLATIN + VINORELBINE | 100982369 |
| 20035904 | 20135045 | 1.81 | 78.6 | Palliative (P) | 2020-01-26 | 2020-02-02 | INTERAACT trial | 02 | N | GEMCITABINE + OXALIPLATIN | 100976070 |
| 20037775 | 20135047 | 1.53 | 62.2 | Adjuvant (A) | 2018-12-12 | 2018-12-22 | CISPLATIN + FLUOROURACIL + RT | N | N | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 101017543 |
| 20039176 | 20135048 | 1.71 | 48.4 | null | 2018-09-09 | 2018-09-19 | Bendamustine + Thalidomide +/- Dex | 02 | null | DURVALUMAB | 101171699 |
| 20039412 | 20135050 | 1.55 | 0 | Neo-adjuvant (N) | 2018-10-07 | 2018-10-13 | CAPECITABINE + IRINOTECAN + Panitumumab | 02 | null | BENDAMUSTINE + CYTARABINE + RITUXIMAB | 101347751 |
| 20039998 | 20135051 | 1.75 | 69.9 | null | 2018-10-25 | 2019-03-10 | CAV | 01 | null | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101839329 |
| 20040304 | 20135052 | 1.49 | 87 | Palliative (P) | 2020-08-03 | 2020-08-03 | Nintedanib | N | N | EW EUROEWING 2012 ARM B IE | 100597632 |
| 20040612 | 20135053 | 1.65 | 74.1 | Curative (C) | 2017-12-28 | 2018-01-18 | PHITT D SIOPEL-4 (A1, A2, A3) | 02 | null | AML18 TRIAL | 101227502 |
| 20044311 | 20135054 | 1.58 | 66.15 | Disease modification (D) | 2020-04-07 | 2020-04-18 | SCOPE 2 TRIAL | 01 | N | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 100223840 |
| 20044417 | 20135055 | 1.8 | 58.9 | null | 2019-06-27 | 2019-06-27 | Cisplatin + Pemetrexed | 2 | null | CISPLATIN + RT | 101641616 |
| 20044980 | 20135056 | null | 72 | null | 2020-06-19 | 2020-06-19 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | DARATUMUMAB | 100160694 |
| 20046134 | 20135057 | 1.69 | 0 | Palliative (P) | 2018-01-09 | 2018-01-09 | EEF or EOF | 02 | N | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 100443890 |
| 20046135 | 20135058 | 1.56 | 64.8 | null | 2022-05-06 | 2022-05-18 | Cetuximab + FLUOROURACIL | 02 | null | GEMCITABINE + RT | 100166988 |
| 20048379 | 20135059 | 1.61 | 51.6 | Adjuvant (A) | null | null | FCarboSt | 02 | N | CISPLATIN + RT | 101181261 |
| 20048721 | 20135060 | 1.51 | 66 | Palliative (P) | 2017-09-16 | 2017-10-24 | CHOP - 21 days | 02 | N | GEMCITABINE + OXALIPLATIN | 101266698 |
| 20049106 | 20135062 | 1.69 | 11 | Palliative (P) | 2018-11-22 | 2018-11-28 | BCG Intravesical | 02 | null | TOPOTECAN | 100467613 |
| 20049933 | 20135063 | 1.81 | 85.1 | Palliative (P) | 2018-05-04 | 2018-05-05 | Capecitabine + Streptozocin | N | N | LETROZOLE + PALBOCICLIB | 100460285 |
| 20051858 | 20135065 | 1.8 | 60 | null | 2015-04-12 | 2017-08-20 | Hepatoblastoma SR Cisplatin | Y | N | ERIBULIN | 101811196 |
| 20051949 | 20135066 | 1.8 | 81.5 | Palliative (P) | 2020-12-22 | 2020-12-23 | TOPOTECAN | 02 | N | FOCUS4 TRIAL | 100930921 |
| 20054258 | 20135067 | 1.55 | 75.75 | Palliative (P) | 2019-09-13 | 2019-09-25 | CISPLATIN + FLUOROURACIL + RT | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101133641 |
| 20054283 | 20135068 | 1.57 | 62.4 | null | 2016-12-22 | 2016-12-30 | COSMIC TRIAL | 02 | null | ECARBOX | 100040411 |
| 20055654 | 20135069 | 1.65 | 75.5 | Palliative (P) | 2019-03-02 | 2019-04-15 | R-GEM-P | 2 | null | CAP + RT | 101690878 |
| 20058058 | 20135071 | 1.83 | 68 | Palliative (P) | 2019-08-10 | 2019-08-25 | Carboplatin + Fluorouracil + Streptozocin | 02 | N | ALECTINIB | 100370115 |
| 20058995 | 20135073 | 1.57 | 113.5 | Curative (C) | 2019-07-09 | 2020-03-01 | Capital Trial | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100995173 |
| 20060314 | 20135074 | 1.8 | 68 | Palliative (P) | 2019-07-13 | 2019-08-26 | ETOPOSIDE | 02 | N | IRINOTECAN + RALTITREXED | 101012068 |
| 20060754 | 20135075 | 1.84 | 75 | Palliative (P) | 2017-11-20 | 2017-11-25 | CAPECITABINE + LOMUSTINE | N | N | PERTUZUMAB + TRASTUZUMAB | 101781127 |
| 20062395 | 20135077 | 1.72 | 144.7 | Curative (C) | 2019-08-06 | 2019-08-06 | Bevacizumab + Capecitabine | 02 | null | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 100680052 |
| 20062437 | 20135078 | 1.6 | 0 | null | 2016-07-12 | 2017-05-25 | Rucaparib | 02 | N | OXALIPLATIN + MDG + PANITUMUMAB | 101004426 |
| 20063027 | 20135080 | 1.66 | 70.1 | Curative (C) | 2019-12-31 | 2020-01-01 | null | 02 | N | CISPLATIN + FU + TRASTUZUMAB | 101669201 |
| 20063333 | 20135081 | 1.55 | 28.6 | null | 2019-07-15 | 2019-07-20 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | N | IPILIMUMAB + NIVOLUMAB | 100792190 |
| 20064678 | 20135083 | 1.6 | 92.1 | null | 2016-05-12 | 2016-05-23 | Olaparib | 01 | N | EOF | 101019356 |
| 20065210 | 20135084 | 1.79 | null | Palliative (P) | 2018-11-15 | 2019-04-04 | TEMOZOLOMIDE | 01 | N | ECF | 100023013 |
| 20065293 | 20135085 | 1.72 | 96 | Curative (C) | 2020-01-20 | 2020-01-20 | VINORELBINE | 02 | N | CAP + RT | 100738854 |
| 20065775 | 20135086 | 1.89 | 53.9 | Neo-adjuvant (N) | 2018-11-15 | 2018-12-19 | Cape+Cetuximab+Oxalip (2 wk) Load | 2 | null | DOCETAXEL + NINTEDANIB | 101764724 |
| 20068958 | 20135087 | 1.57 | 68.6 | Palliative (P) | 2018-09-29 | 2018-10-26 | CYCLOPHOSPHAMIDE + VINORELBINE | 99 | N | IRINOTECAN + PANITUMUMAB | 101387348 |
| 20073243 | 20135089 | 1.72 | 0 | Palliative (P) | 2019-01-10 | 2019-01-11 | Carboplatin + Pemetrexed | 02 | N | EPIRUBICIN | 100198859 |